Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Effects of the treatments 3.2.1
Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play
J Endocrinol Invest 34: 876-880
Most elective surgeries require stopping GLP-1 medications 24 to 72 hours before the procedure to reduce aspiration risk and anesthesia interactions
Wan Y, Wang Q, Prud'homme GJ
